Nov 13 (Reuters) - Aclaris Therapeutics on Monday said it will stop development of its rheumatoid arthritis treatment after it failed in a mid-stage trial. (Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel)
There's a much more popular AI stock on Capitol Hill than the leading AI chip maker.
Donald Trump’s aides have drawn up secret plans to oust the chairman of the Federal Reserve and allow the president to set interest rates, according to reports.
The $50 million purchase could turn into Nvidia's biggest investment.
These proven wealth builders could be exactly what you're searching for right now.
The property report includes 85 major metropolitan areas in the U.S. with populations of at least 750,000.
Walmart's CEO went from earning $6.50 an hour to $25 million a year—here are his three tips for climbing the corporate ladder like him
Jamie Dimon and Jerome Powell are taking the European viewpoint on soaring debt levels in the U.S.
The JPMorgan Nasdaq Equity Premium Income ETF offers a compelling blend of income and upside to my portfolio.
There are benefits to investing in stocks that have reasonable multiples and aren't as dependent on future earnings growth to justify their valuations.
Here's what could happen next to Microsoft shares.